Additional Treatment Modality to Improve Outcomes in Myocardial Infarctions and Strokes

• 作者: Boris Skurkovich Simon Skurkovich
• 来源期刊: 基于免疫的治疗疫苗和抗菌期刊(英文)
• 学科: 医学
• 关键词: NEUTRALIZATION of PRO-INFLAMMATORY CYTOKINES MYOCARDIAL INFARCTION Stroke
• 年，卷（期）: 2014,（2）
• 页码范围: 29-31
• 页数: 3页
• 分类号: R5

摘要

In 1974, in Nature, we hypothesized that removal of cytokines can be effective in the treatment of certain inflammatory diseases, e.g., rheumatoid arthritis (RA). We call this approach anticytokino-therapy. Later it was shown that neutralization of pro-inflammatory cytokines, such as tumor necrosis factor alpha (TNF-α), interferon alpha (IFN-α), interferon gamma (IFN-γ), and interleukin 6 (IL-6), leads to a good therapeutic effect. Anticytokinotherapy is currently used around the world for the treatment of rheumatoid arthritis, psoriasis, psoriatic arthritis, and other Th-1-mediated inflammatory diseases. Pro-inflammatory cytokines have also been found in other conditions (myocardial infarctions, strokes, chronic pain syndromes, etc.). This leads us to believe that hyper- production of pro-inflammatory cytokines forms a basis of a variety of pathological conditions and represents a uniform response of the organism to a wide variety of insults in any part of the body. Thus, we propose to add monoclonal antibodies to (or other blockers of) pro-inflammatory cytokines to the treatment regimens for myocardial infarctions, strokes, and possibly other Th-1-mediated diseases.